Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Baxter
Healthtrust
Fish and Richardson
McKinsey
Cipla
Moodys
UBS
Julphar

Generated: June 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020182

« Back to Dashboard

NDA 020182 describes CARNITOR, which is a drug marketed by Leadiant Biosci Inc and is included in three NDAs. It is available from two suppliers. There are three patents protecting this drug. Additional details are available on the CARNITOR profile page.

The generic ingredient in CARNITOR is levocarnitine. There are four drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the levocarnitine profile page.
Summary for 020182
Tradename:CARNITOR
Applicant:Leadiant Biosci Inc
Ingredient:levocarnitine
Patents:3
Formulation / Manufacturing:see details
Pharmacology for NDA: 020182
Ingredient-typeCarnitine
Suppliers and Packaging for NDA: 020182
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CARNITOR levocarnitine INJECTABLE;INJECTION 020182 NDA Leadiant Biosciences, Inc. 54482-147 N 54482-147-01

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength200MG/ML
Approval Date:Dec 16, 1992TE:APRLD:Yes
Patent:➤ Sign UpPatent Expiration:Jan 18, 2021Product Flag?Substance Flag?Delist Request?
Patented Use:USE OF LEVOCARNITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
Patent:➤ Sign UpPatent Expiration:Jan 18, 2021Product Flag?Substance Flag?Delist Request?
Patented Use:USE OF LEVOCARNITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS
Patent:➤ Sign UpPatent Expiration:Jan 18, 2021Product Flag?Substance Flag?Delist Request?
Patented Use:USE OF LEVOCARNITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
US Army
Julphar
Citi
Deloitte
Dow
UBS
Medtronic
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.